This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Google Scholar Articles by Muhlhausler, B. S. Articles by McMillen, I. C. PubMed PubMed Citation Articles by Muhlhausler, B. S. Articles by McMillen, I. C.

Rosiglitazone Increases the Expression of Peroxisome Proliferator-Activated Receptor- Target Genes in Adipose Tissue, Liver, and Skeletal Muscle in the Sheep Fetus in Late Gestation

Early Origins of Adult Health Research Group, Sansom Institute for Health Research, University of South Australia, Adelaide 5000, Australia

Address all correspondence and requests for reprints to: Dr. Beverly Muhlhausler, Sansom Research Institute, University of South Australia, Adelaide 5000, Australia. E-mail: Beverly.Muhlhausler{at}unisa.edu.au.

Exposure to maternal overnutrition increases the expression of peroxisome proliferator-activated receptor- (PPAR) in adipose tissue before birth, and it has been proposed that the precocial activation of PPAR target genes may lead to increased fat deposition in postnatal life. In this study, we determined the effect of intrafetal administration of a PPAR agonist, rosiglitazone, on PPAR target gene expression in fetal adipose tissue as well indirect actions of rosiglitazone on fetal liver and skeletal muscle. Osmotic pumps containing rosiglitazone (n = 7) or vehicle (15% ethanol, n = 7) were implanted into fetuses at 123–126 d gestation (term = 150 ± 3 d gestation). At 137–141 d gestation, tissues were collected and mRNA expression of PPAR, lipoprotein lipase (LPL), adiponectin, and glycerol-3-phosphate dehydrogenase (G3PDH) in adipose tissue, PPAR and PPAR-coactivator 1 (PGC1) in liver and muscle and phosphoenolpyruvate carboxykinase (PEPCK) in liver determined by quantitative real-time RT-PCR. Plasma insulin concentrations were lower in rosiglitazone-treated fetuses (P < 0.02). Rosiglitazone treatment resulted in increased expression of LPL and adiponectin mRNA (P < 0.01) in fetal adipose tissue. The expression of PPAR mRNA in liver (P < 0.05) and PGC1 mRNA (P < 0.02) in skeletal muscle were also increased by rosiglitazone treatment. Rosiglitazone treatment increased expression of PPAR target genes within fetal adipose tissue and also had direct or indirect actions on the fetal liver and muscle. The effects of activating PPAR in fetal adipose tissue mimic those induced by prenatal overnutrition, and it is therefore possible that activation of PPAR may be the initiating mechanism in the pathway from prenatal overnutrition to postnatal obesity.